News | Heart Failure | July 13, 2017

Vest Wearable Monitor May Reduce Heart Failure Readmissions

The SensiVest uses radar technology to detect the exact amount of fluid in the lungs

monitoring a heart failure patient's chest fluid buildup with remote monitoring using the SensiVest

A heart failure patient wearing the SensiVest remote monitoring system for a two-minute a day assessment. 

William Abraham monitoring a heart failure patient's chest fluid buildup with remote monitoring using the SensiVest

William Abraham, M.D., monitoring a heart failure patient's chest fluid buildup using the SensiVest remote monitoring system. The daily data points can show if a patient is starting to retain fluids prior to the onset of symptoms.

July 13, 2017 — About 5.7 million adults in the U.S. suffer from heart failure, and because of a dangerous buildup of fluid in their lungs, more than half of those patients end up back in the hospital within six months. But researchers say a high-tech vest that is entering U.S. trials may help doctors monitor a heart patient’s symptoms remotely, which may prevent the need for rehospitalization.

The SMILE Trial (Sensible Medical Innovations Lung fLuid status monitor allows rEducing readmission rate of heart failure patients study) will look at the efficacy of the SensiVest, a product developed by Sensible Medical Innovations, headquartered in Israel. The system is comprised of a wearable vest containing two embedded sensors, one in front and one behind the patient, and a bedside console. 

“The major cause of readmission for heart failure patients is excess fluid in the lungs,” said William Abraham, M.D., FACC, director of the Division of Cardiovascular Medicine at The Ohio State University Wexner Medical Center, who is leading a randomized, clinical trial of the vest. “The vest allows us to see when the lungs are trending toward being too wet so a patient’s medication can be adjusted before they even notice any symptoms.”

Watch a VIDEO showing how the vest works and to hear more about it from Abraham.

The vest uses radar technology to “see through” the chest and accurately detect the amount of fluid in the lungs. A patient wears the vest for just 90 seconds a day and the information collected is automatically uploaded to a cloud server. The patient’s cardiologist can review the data to determine if any treatment adjustments need to be made to restore the lungs to healthy fluid levels.

“This technology gives us absolute and actionable data of lung fluid content that we can use to keep patients healthy and out of the hospital,” Abraham said. “The fact that it is completely non-invasive and takes less than two minutes a day to use, allows patients to live a better quality of life with heart failure.”

A study initially conducted in Israel reported that hospital readmission rates were reduced by 87 percent for patients who were part of the study. 

The vest uses the same technology used by the military for things like “seeing through” walls before entering a building or searching through rubble for survivors after a natural disaster.

Watch a VIDEO discussion with Abraham on several new technologies to treat HF and reduce heart failure readmissions from TCT 2016.

Read the article "Reducing Heart Failure Readmissions."

Related Content

Examples of  allogeneic cardiac cells (also called cardiosphere-derived cells or CDCs).

Examples of allogeneic cardiac cells (also called cardiosphere-derived cells or CDCs), that were used to treat heart attack infarcts to reverse heart failure in the ALLSTAR trial.

News | Heart Failure | August 04, 2020
August 4, 2020 - More than three years after a clinical trial was prematurely ended for failing to show progress in h
News | Heart Failure | July 09, 2020
July 9, 2020 – The Minneapolis Heart Institute Foundation (MHIF) is conducting additional research on a novel hydroge
Navin Kapur, M.D., Tufts Medical Center, shows preCardia device and its anatomical positioning in the patient to treat heart failure..

Navin Kapur, M.D., Tufts Medical Center, shows preCardia device and its anatomical positioning in the patient.

News | Heart Failure | June 23, 2020
June 23, 2020 — The U.S.
Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) #ACC20/#WCCardio
News | Heart Failure | March 29, 2020
March 29, 2020 — Patients with worsening heart failure and reduced ejection fraction who received the investigational
Dapagliflozin Reduces Heart Failure Worsening and Death in DAPA-HF Sub-analysis. #ACC20 #ACC2020
News | Heart Failure | March 28, 2020
March 28, 2020 — New data from a sub-analysis of the landmark Phase III...
News | Heart Failure | March 05, 2020
March 5, 2020 — Abbott recently received Breakthrough Device designation from the U.S.
Some of the new devices technologies to treat heart failure that are either in clinical trials or were recently cleared by the U.S. FDA. #heartfailure

Some of the new devices technologies to treat heart failure that are either in clinical trials or were recently cleared by the U.S. FDA. 

Feature | Heart Failure | February 21, 2020 | Dave Fornell, Editor
There are several new tools being added to the clinical armamentarium in the fight against...
Tufts Medical Center created a heart failure team approach to care for its patients. The program includes an interventional heart failure fellowship program, where interventional cardiologists learn more advanced care, as show here with an ECMO procedure being performed in a cath lab at Tufts. The interventional cardiologists learn how to better care for heart failure patients and interface with surgeons, intensivists and others on the HF care team. The operator is Nevin Kapur. Photo by Dave Fornell.

Tufts Medical Center created a heart failure team approach to care for its patients. The program includes an interventional heart failure fellowship program, where interventional cardiologists learn more advanced hemodynamic support methods, as shown here with an ECMO procedure being performed in a cath lab at Tufts. The interventional cardiologists learn how to better care for heart failure patients and interface with surgeons, intensivists and others on the HF care team. Photo by Dave Fornell.

Feature | Heart Failure | February 20, 2020 | Dave Fornell, Editor
There is no, single magic bullet in heart failure (HF) to easily reduce readmission rates or easily reverse this...